Faster Determination Of Dynamic Binding Capacity
Today’s pharmaceutical industry is a competitive landscape for biopharma companies, with a high cost of entry and the need for substantial financial investments in research and development (R&D).
KBI Biopharma, a CDMO, has a team of experts who are streamlining and revolutionizing the process development of biomolecules every day. The KBI team wanted to find a way to streamline the downstream process for biopharmaceuticals using variable pathlength technology to determine the DBC of affinity chromatography resins to produce reliable data more effectively and efficiently.
The team published their results in the paper Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals. Their work provides a verified protocol and comprehensive analysis for rapidly determining DBC for various molecules (including mAbs and fusion proteins) on capture chromatography resins using the FlowVPE spectrophotometer based on inline variable pathlength technology.4
The team shares more insights on their research in this Q&A.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.